UNITED THERAPEUTICS Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $548.95 ($542.73–$556.48, $5.22M total) across 14 trades on 2026-10-07 under a Rule 10b5-1 trading plan.
RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $538.67 ($527.90–$545.50, $5.12M total) across 17 trades on 2026-10-06 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning UTHR (UNITED THERAPEUTICS Corp). Coverage has been balanced: 3 bullish, 3 neutral, and 3 bearish.
Recent UTHR coverage spans insider activity, financial news and regulation.
In the last 30 days, UTHR insiders filed 278 SEC Form 4 transactions — no purchases and 278 sales ($110.3M). The most active reporter was ROTHBLATT MARTINE A, Chairperson & CEO, with 259 filings. 99% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale suggests potential downside pressure on United Therapeutics as the CEO reduces her stake.
Analyst price‑target increase may support short‑term upside.
The insider sale may signal reduced confidence and could pressure the stock lower in the short term.
The ruling removes regulatory uncertainty for United Therapeutics' Remodulin supply chain.
The verdict removes a key legal risk to United Therapeutics' PH-ILD treatment market.
AlphAI scores every news story that mentions UTHR with an AI model for sentiment and relevance, and aggregates insider trades from UNITED THERAPEUTICS Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $548.95 ($542.73–$556.48, $5.22M total) across 14 trades on 2026-10-07 under a Rule 10b5-1 trading plan.
1 min readRBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $538.67 ($527.90–$545.50, $5.12M total) across 17 trades on 2026-10-06 under a Rule 10b5-1 trading plan.
1 min readUnited Therapeutics' acquisition of cartridges for Remodulin was upheld by a US appeals court, dismissing Sandoz's antitrust claims. The court found UTC's justifications procompetitive, aiming to secure supply for its product.
1 min readMcDermott Will & Schulte won a patent trial for United Therapeutics (UTC) against Liquidia, with a court ruling that Liquidia infringed on UTC's patent for PH-ILD treatment. The decision may impact Liquidia's ability to market YUTREPIA®. UTC has previously won similar cases against Liquidia.
2 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $541.64 ($536.26–$546.63, $5.15M total) across 11 trades on 2026-10-05 under a Rule 10b5-1 trading plan.
1 min readAn insider of United Therapeutics sold shares worth $5.22 million, as disclosed in a recent SEC filing. The company's stock is currently trading at $536.40, with a 5-day change of -0.98% and a year-to-date change of +12.82%.
1 min readUnited Therapeutics (UTHR) CEO Martine A. Rothblatt exercised 9,500 stock options and sold the resulting shares, totaling 9,500 common shares, on October 2, 2026. The sales were part of a pre-arranged 10b5-1 plan adopted in November 2025. The average sale price was approximately $542.0614 per share, with the total value of the sales reported at $379K.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $549.37 ($542.06–$574.22, $5.22M total) across 23 trades on 2026-10-02 under a Rule 10b5-1 trading plan.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $576.47 ($560.05–$584.66, $5.48M total) across 19 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min read
